Genmab Drug Combo Cuts DLBCL Progression/Death Risk by 51% in Phase 3
Genmab reported topline Phase 3 data showing epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed DLBCL patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.